Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide for Human Immunodeficiency Virus Preexposure Prophylaxis at a Boston Community Health Center

BACKGROUND: Efforts to end the human immunodeficiency virus (HIV) epidemic may be threatened if limited preexposure prophylaxis (PrEP) resources are funneled from tenofovir disoproxil fumarate with emtricitabine (TDF/FTC) to tenofovir alafenamide with emtricitabine (TAF/FTC) without proportional cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Marcus, Julia L, Levine, Kenneth, Sewell, Whitney C, Solleveld, Patricia, Mayer, Kenneth H, Krakower, Douglas S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Major Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496521/
https://www.ncbi.nlm.nih.gov/pubmed/34631926
http://dx.doi.org/10.1093/ofid/ofab372

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496521/
https://www.ncbi.nlm.nih.gov/pubmed/34631926
http://dx.doi.org/10.1093/ofid/ofab372

Ejemplares similares